Evidence map›Paper›PMID 30841919›Full record

ArticleBreast cancer research : BCR2019

Separation of breast cancer and organ microenvironment transcriptomes in metastases.

Mohammad A Alzubi, Tia H Turner, Amy L Olex, Sahib S Sohal, Nicholas P Tobin, Susana G Recio, Jonas Bergh, Thomas Hatschek, Joel S Parker, Carol A Sartorius and 3 more

Open access · goldAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Review
  3. Therapeutic synergies that overcome carboplatin resistance in triple-negative breast cancer.Journal of experimental & clinical cancer research : CR · 2026
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Mohammad A AlzubiDepartment of Pathology, Virginia Commonwealth University, Richmond, VA, USA.
Tia H TurnerDepartment of Pathology, Virginia Commonwealth University, Richmond, VA, USA.
Amy L OlexC. Kenneth and Dianne Wright Center for Clinical and Translational Research, Virginia Commonwealth University, Richmond, VA, USA.
Sahib S SohalDepartment of Pathology, Virginia Commonwealth University, Richmond, VA, USA.
Nicholas P TobinDepartment of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institutet and University Hospital, Stockholm, Sweden.
Susana G RecioDepartment of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Jonas BerghDepartment of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institutet and University Hospital, Stockholm, Sweden.
Thomas HatschekDepartment of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institutet and University Hospital, Stockholm, Sweden.
Joel S ParkerDepartment of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Carol A SartoriusDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Charles M PerouDepartment of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Mikhail G DozmorovDepartment of Biostatistics, Virginia Commonwealth University, Richmond, VA, USA.
J Chuck HarrellDepartment of Pathology, Virginia Commonwealth University, Richmond, VA, USA. joshua.harrell@vcuhealth.org.ORCID 0000-0003-3541-8418
Virginia Commonwealth University · USKarolinska University Hospital · SEUniversity of North Carolina at Chapel Hill · USUniversity of Colorado Anschutz Medical Campus · US

Funding

Tissue Procurement & PathologyP50CA058223 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KATHERINE A. HOADLEY · 1992 to 2026
$59.3M
Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Keri R Maher · 1985 to 2026
$51.0M
Research Supplement to Promote Diversity in Health Related ResearchUL1TR002649 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2018 to 2022
$19.1M
Therapeutic Targeting of Breast Cancer Tumor Initiating CellsR01CA148761 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PEROU, CHARLES M, ROSEN, JEFFREY MARK · 2010 to 2025
$6.5M
Hormones and Tumor Initiating Cells in Human Breast CancersR01CA140985 · NCI · UNIVERSITY OF COLORADO DENVER · PI SARTORIUS, CAROL ANN · 2011 to 2020
$3.0M
Mouse Models of Metastatic Triple-Negative Breast Cancer for Therapeutic TestingR01CA195754 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PEROU, CHARLES M, ROSEN, JEFFREY MARK · 2015 to 2017
$1.7M
NCATS NIH HHS UL1 TR002649NCATS NIH HHS UL1TR002649NCI NIH HHS P30 CA016059NCI NIH HHS P50 CA058223NCI NIH HHS P50-CA58223NCI NIH HHS R01 CA140985NCI NIH HHS R01 CA148761NCI NIH HHS R01 CA195754NCI NIH HHS R01-CA195754NCI NIH HHS RO1-CA148761
6 · The paper itself

Abstract

backgroundThe seed and soil hypothesis was proposed over a century ago to describe why cancer cells (seeds) grow in certain organs (soil). Since then, the genetic properties that define the cancer cells have been heavily investigated; however, genomic mediators within the organ microenvironment that mediate successful metastatic growth are less understood. These studies sought to identify cancer- and organ-specific genomic programs that mediate metastasis.

methodsIn these studies, a set of 14 human breast cancer patient-derived xenograft (PDX) metastasis models was developed and then tested for metastatic tropism with two approaches: spontaneous metastases from mammary tumors and intravenous injection of PDX cells. The transcriptomes of the cancer cells when growing as tumors or metastases were separated from the transcriptomes of the microenvironment via species-specific separation of the genomes. Drug treatment of PDX spheroids was performed to determine if genes activated in metastases may identify targetable mediators of viability.

resultsThe experimental approaches that generated metastases in PDX models were identified. RNA sequencing of 134 tumors, metastases, and normal non-metastatic organs identified cancer- and organ-specific genomic properties that mediated metastasis. A common genomic response of the liver microenvironment was found to occur in reaction to the invading PDX cells. Genes within the cancer cells were found to be either transiently regulated by the microenvironment or permanently altered due to clonal selection of metastatic sublines. Gene Set Enrichment Analyses identified more than 400 gene signatures that were commonly activated in metastases across basal-like PDXs. A Src signaling signature was found to be extensively upregulated in metastases, and Src inhibitors were found to be cytotoxic to PDX spheroids.

conclusionsThese studies identified that during the growth of breast cancer metastases, there were genomic changes that occurred within both the cancer cells and the organ microenvironment. We hypothesize that pathways upregulated in metastases are mediators of viability and that simultaneously targeting changes within different cancer cell pathways and/or different tissue compartments may be needed for inhibition of disease progression.

Indexed as

AnimalsBreastBreast NeoplasmsDatasets as TopicDisease ProgressionFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLiverLiver NeoplasmsLungLung NeoplasmsMiceTranscriptomeTumor Cells, CulturedBreast cancerLuciferaseMetastasisMicroenvironmentPatient-derived xenograftRNA sequencing

Identifiers

PMID30841919
PMCPMC6404325
OpenAlexW2924813631

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.